Evidence map›Paper›PMID 41521763›Full record

ArticleJournal of cosmetic dermatology2026

Rising Public Interest in Weight Loss Medications and Growing Awareness of Their Aesthetic Sequelae: An Infodemiologic Google Trends Analysis and Clinical Diagnostic Patterning.

Alec D McCarthy, Kay Durairaj, Jacob Linneman-Heath, Dusan Sajic, Mara Dacso, Alan Durkin

Abstract read
In one paragraph

Article in Journal of cosmetic dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Alec D McCarthyGlobal Medical Affairs, Merz Aesthetics, Raleigh, North Carolina, USA.ORCID https://orcid.org/0000-0002-5063-5413
Kay DurairajK. Kay Durairaj, M.D., A Medical Corp, Pasadena, California, USA.ORCID https://orcid.org/0009-0004-1287-8619
Jacob Linneman-HeathGlobal Medical Affairs, Merz Aesthetics, Raleigh, North Carolina, USA.ORCID https://orcid.org/0009-0003-4348-4711
Dusan SajicDerma Skin Institute, Guelph, Ontario, Canada.
Mara DacsoInnovative Dermatology, Plano, Texas, USA.ORCID https://orcid.org/0000-0003-0999-4278
Alan DurkinOcean Drive Plastic Surgery, Dermatology, and MedSpa, Vero Beach, Florida, USA.ORCID https://orcid.org/0000-0002-1675-9519

Funding

Merz Aesthetics
6 · The paper itself

Abstract

backgroundGlucagon-like peptide-1 receptor agonists (GLP-1 RAs) have gained rapid popularity for both medical and consumer-directed weight loss. This growth has been accompanied by increased public discussion regarding facial aesthetic changes, commonly referred to as "Ozempic face," characterized by volume depletion and cutaneous laxity.

objectiveTo quantify temporal patterns of public search interest in a widely known GLP-1 RA and evaluate corresponding awareness of its cosmetic facial sequelae using infodemiologic methods.

methodsGoogle Trends data for "Ozempic" and related frequently co-searched queries were analyzed from November 2021 to December 2024. Trends in relative search volume (RSV) were examined, with particular focus on terms associated with facial aesthetics, including "Ozempic face" and "plastic surgeons Ozempic face."

resultsRSV for "Ozempic" showed a steady upward trajectory over the study period. Queries related to facial aesthetic consequences exhibited substantial proportional increases. Notably, "Ozempic face" demonstrated a 4600% rise in RSV, and searches for "plastic surgeons Ozempic face" similarly grew markedly.

conclusionsPublic interest in GLP-1 RAs is strongly associated with rising awareness and concern about their facial aesthetic effects. These trends suggest that aesthetic practitioners should expect more patient inquiries regarding GLP-1-related facial changes and should proactively integrate counseling and corrective treatment options into clinical practice.

Indexed as

Anti-Obesity AgentsEstheticsGlucagon-Like Peptide-1 Receptor AgonistsSearch EngineFaceHumansInternetSemaglutideAnti-Obesity AgentsGlucagon-Like Peptide-1 Receptor AgonistsSemaglutidebiostimulatorsglucagon‐like peptide‐1 receptor agonistsGoogle trendsOzempic facepublic interest

Identifiers

PMID41521763
PMCPMC12793942

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.